Correlation between the expression of Ki67 and histopathological grade, tumor size, disease-free survival, and overall survival among breast cancer patients.

Breast disease Pub Date : 2022-01-01 DOI:10.3233/BD-229005

Radityo Budi Leksono, Rudy Thabry, Prihantono Prihantono, Fritz Nahusuly, Firdaus Kasim, William Hamdani, John Pieter, Indra Indra, Salman Ardi Syamsu, Muhammad Faruk

{"title":"Correlation between the expression of Ki67 and histopathological grade, tumor size, disease-free survival, and overall survival among breast cancer patients.","authors":"Radityo Budi Leksono, Rudy Thabry, Prihantono Prihantono, Fritz Nahusuly, Firdaus Kasim, William Hamdani, John Pieter, Indra Indra, Salman Ardi Syamsu, Muhammad Faruk","doi":"10.3233/BD-229005","DOIUrl":null,"url":null,"abstract":"Introduction: Identifying Ki67, a monoclonal antibody that recognizes proliferating cells, is important for defining the level of proliferative activity among patients with breast cancer. The purpose of our study was to evaluate the correlation between Ki67's expression and histopathological grade, tumor size, disease-free survival (DFS), and overall survival (OS) among breast cancer patients.Methods: Our retrospective cohort study involved examining 114 patients with breast cancer at our institution from January 2018 to December 2019. Participants were retrospectively followed to determine the progression of their disease, and their 2-year progress was examined with survival analysis, especially regarding whether they had postoperative relapse (i.e., DFS) or had died since being diagnosed (i.e., OS). The data were processed with a chi-square test and Kaplan-Meier test, with significance set at p < 0.05.Result: The overexpression of Ki67 correlated significantly with histopathological grade (p = 0.001), tumor size (p = 0.001), DFS (p = 0.001), and OS (p = 0.003).Conclusion: Ki67's overexpression is significantly correlated with the tumor size, DFS, and OS of patients with breast cancer.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-229005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Identifying Ki67, a monoclonal antibody that recognizes proliferating cells, is important for defining the level of proliferative activity among patients with breast cancer. The purpose of our study was to evaluate the correlation between Ki67's expression and histopathological grade, tumor size, disease-free survival (DFS), and overall survival (OS) among breast cancer patients.

Methods: Our retrospective cohort study involved examining 114 patients with breast cancer at our institution from January 2018 to December 2019. Participants were retrospectively followed to determine the progression of their disease, and their 2-year progress was examined with survival analysis, especially regarding whether they had postoperative relapse (i.e., DFS) or had died since being diagnosed (i.e., OS). The data were processed with a chi-square test and Kaplan-Meier test, with significance set at p < 0.05.

Result: The overexpression of Ki67 correlated significantly with histopathological grade (p = 0.001), tumor size (p = 0.001), DFS (p = 0.001), and OS (p = 0.003).

Conclusion: Ki67's overexpression is significantly correlated with the tumor size, DFS, and OS of patients with breast cancer.

查看原文本刊更多论文

乳腺癌患者中Ki67表达与组织病理分级、肿瘤大小、无病生存期和总生存期的相关性

鉴定Ki67是一种识别增殖细胞的单克隆抗体，对于确定乳腺癌患者的增殖活性水平非常重要。我们的研究目的是评估Ki67的表达与乳腺癌患者的组织病理学分级、肿瘤大小、无病生存期(DFS)和总生存期(OS)的相关性。方法:我们的回顾性队列研究纳入了2018年1月至2019年12月在我院就诊的114例乳腺癌患者。回顾性随访参与者以确定其疾病的进展，并通过生存分析检查他们的2年进展，特别是关于他们是否有术后复发(即DFS)或自诊断以来死亡(即OS)。资料采用卡方检验和Kaplan-Meier检验，显著性p < 0.05。结果:Ki67过表达与组织病理分级(p = 0.001)、肿瘤大小(p = 0.001)、DFS (p = 0.001)、OS (p = 0.003)相关。结论:Ki67过表达与乳腺癌患者肿瘤大小、DFS、OS有显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.